Renal toxicity of protease inhibitors

Ali J. Olyaei, Angelo M DeMattos, William M. Bennett

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

Introduction of several classes of antiviral agents for the treatment of immunodeficiency virus has led to increased survival and improved quality of life for patients with HIV infection. Protease inhibitors have become the mainstays of current therapy in patient with AIDS. Renal intolerance of indinavir is a rare but important complication in HIV positive patients. The renal function of patients receiving indinavir should be closely monitored. Benign and asymptomatic crystalluria occurs in 4-13% of HIV positive patients. Several cases of acute renal failure, renal atrophy and interstitial nephritis have also been reported. A hydration protocol consisting of one to two liters of fluid should be initiated three hours after each indinavir dose. If significant renal insufficiency persists, temporary indinavir withdrawal or switching to another protease inhibitor should be considered. (C) 2000 Lippincott Williams and Wilkins.

Original languageEnglish (US)
Pages (from-to)473-476
Number of pages4
JournalCurrent Opinion in Nephrology and Hypertension
Volume9
Issue number5
DOIs
StatePublished - 2000
Externally publishedYes

Fingerprint

Indinavir
Protease Inhibitors
Kidney
HIV
Interstitial Nephritis
Acute Kidney Injury
HIV Infections
Atrophy
Renal Insufficiency
Antiviral Agents
Acquired Immunodeficiency Syndrome
Quality of Life
Viruses
Survival
Therapeutics

ASJC Scopus subject areas

  • Nephrology
  • Internal Medicine

Cite this

Renal toxicity of protease inhibitors. / Olyaei, Ali J.; DeMattos, Angelo M; Bennett, William M.

In: Current Opinion in Nephrology and Hypertension, Vol. 9, No. 5, 2000, p. 473-476.

Research output: Contribution to journalArticle

Olyaei, Ali J. ; DeMattos, Angelo M ; Bennett, William M. / Renal toxicity of protease inhibitors. In: Current Opinion in Nephrology and Hypertension. 2000 ; Vol. 9, No. 5. pp. 473-476.
@article{3fadf4bbce6c46dfb9fda5bc77674440,
title = "Renal toxicity of protease inhibitors",
abstract = "Introduction of several classes of antiviral agents for the treatment of immunodeficiency virus has led to increased survival and improved quality of life for patients with HIV infection. Protease inhibitors have become the mainstays of current therapy in patient with AIDS. Renal intolerance of indinavir is a rare but important complication in HIV positive patients. The renal function of patients receiving indinavir should be closely monitored. Benign and asymptomatic crystalluria occurs in 4-13{\%} of HIV positive patients. Several cases of acute renal failure, renal atrophy and interstitial nephritis have also been reported. A hydration protocol consisting of one to two liters of fluid should be initiated three hours after each indinavir dose. If significant renal insufficiency persists, temporary indinavir withdrawal or switching to another protease inhibitor should be considered. (C) 2000 Lippincott Williams and Wilkins.",
author = "Olyaei, {Ali J.} and DeMattos, {Angelo M} and Bennett, {William M.}",
year = "2000",
doi = "10.1097/00041552-200009000-00003",
language = "English (US)",
volume = "9",
pages = "473--476",
journal = "Current Opinion in Nephrology and Hypertension",
issn = "1062-4821",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - Renal toxicity of protease inhibitors

AU - Olyaei, Ali J.

AU - DeMattos, Angelo M

AU - Bennett, William M.

PY - 2000

Y1 - 2000

N2 - Introduction of several classes of antiviral agents for the treatment of immunodeficiency virus has led to increased survival and improved quality of life for patients with HIV infection. Protease inhibitors have become the mainstays of current therapy in patient with AIDS. Renal intolerance of indinavir is a rare but important complication in HIV positive patients. The renal function of patients receiving indinavir should be closely monitored. Benign and asymptomatic crystalluria occurs in 4-13% of HIV positive patients. Several cases of acute renal failure, renal atrophy and interstitial nephritis have also been reported. A hydration protocol consisting of one to two liters of fluid should be initiated three hours after each indinavir dose. If significant renal insufficiency persists, temporary indinavir withdrawal or switching to another protease inhibitor should be considered. (C) 2000 Lippincott Williams and Wilkins.

AB - Introduction of several classes of antiviral agents for the treatment of immunodeficiency virus has led to increased survival and improved quality of life for patients with HIV infection. Protease inhibitors have become the mainstays of current therapy in patient with AIDS. Renal intolerance of indinavir is a rare but important complication in HIV positive patients. The renal function of patients receiving indinavir should be closely monitored. Benign and asymptomatic crystalluria occurs in 4-13% of HIV positive patients. Several cases of acute renal failure, renal atrophy and interstitial nephritis have also been reported. A hydration protocol consisting of one to two liters of fluid should be initiated three hours after each indinavir dose. If significant renal insufficiency persists, temporary indinavir withdrawal or switching to another protease inhibitor should be considered. (C) 2000 Lippincott Williams and Wilkins.

UR - http://www.scopus.com/inward/record.url?scp=0033849729&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033849729&partnerID=8YFLogxK

U2 - 10.1097/00041552-200009000-00003

DO - 10.1097/00041552-200009000-00003

M3 - Article

C2 - 10990364

AN - SCOPUS:0033849729

VL - 9

SP - 473

EP - 476

JO - Current Opinion in Nephrology and Hypertension

JF - Current Opinion in Nephrology and Hypertension

SN - 1062-4821

IS - 5

ER -